C4 Therapeutics, Inc. - 8-K Filing
C4 Therapeutics reported first-quarter 2026 financial results with revenue of $6.2 million and a net loss of $25.1 million ($0.20 per share). The company announced plans to initiate an additional Phase 1b trial for cemsidomide in combination with approved multiple myeloma therapies by mid-2027, while enrollment is ongoing in the Phase 2 MOMENTUM trial and a new Phase 1b trial combining cemsidomide with elranatamab. The company also secured an upfront $20 million payment from Roche under a collaboration agreement for degrader-antibody conjugates. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $CCCC